Carbon monoxide inhibits T lymphocyte proliferation via caspase-dependent pathway

J Immunol. 2004 Jan 15;172(2):1220-6. doi: 10.4049/jimmunol.172.2.1220.

Abstract

T lymphocyte activation and proliferation is involved in many pathological processes. We have recently shown that carbon monoxide (CO), an enzymatic product of heme oxygenase-1 (HO-1), confers potent antiproliferative effects in airway and vascular smooth muscle cells. The purpose of this study was to determine whether CO can inhibit T lymphocyte proliferation and then to determine the mechanism by which CO can modulate T lymphocyte proliferation. In the presence of 250 parts per million CO, CD3-activated T lymphocyte proliferation was, remarkably, inhibited by 80% when compared with controls. We observed that the antiproliferative effect of CO in T lymphocytes was independent of the mitogen-activated protein kinase or cGMP signaling pathways, unlike what we demonstrated previously in smooth muscle cells. We demonstrate that CO inhibited caspase-3 and caspase-8 expression and activity, and caspase inhibition with benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (Z-VAD-FMK pan-caspase inhibitor) blocked T lymphocyte proliferation. Furthermore, in caspase-8-deficient lymphocytes, the antiproliferative effect of CO was markedly attenuated, further supporting the involvement of caspase-8 in the antiproliferative effects of CO. CO also increased the protein level of p21(Cip1), and CO-mediated inhibition of caspase activity is partially regulated by p21(Cip1). Taken together, these data suggest that CO confers potent antiproliferative effects in CD3-activated T lymphocytes and that these antiproliferative effects in T lymphocytes are mediated by p21(Cip1)-dependent caspase activity, in particular caspase-8, independent of cGMP and mitogen-activated protein kinase signaling pathways.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Carbon Monoxide / toxicity*
  • Caspase 8
  • Caspase Inhibitors
  • Caspases / physiology*
  • Cells, Cultured
  • Cyclic GMP / biosynthesis
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins / biosynthesis
  • Enzyme Activation / drug effects
  • Enzyme Activation / immunology
  • Enzyme Inhibitors / toxicity
  • Growth Inhibitors / toxicity*
  • Guanylate Cyclase / metabolism
  • Guanylate Cyclase / physiology
  • Humans
  • Immunosuppressive Agents / toxicity*
  • JNK Mitogen-Activated Protein Kinases*
  • Jurkat Cells
  • Lymphocyte Activation / drug effects
  • MAP Kinase Kinase 4
  • MAP Kinase Kinase Kinase 3
  • MAP Kinase Kinase Kinases / physiology
  • MAP Kinase Signaling System / drug effects
  • MAP Kinase Signaling System / immunology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mitogen-Activated Protein Kinase Kinases / physiology
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / enzymology*
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism
  • Up-Regulation / drug effects
  • Up-Regulation / immunology

Substances

  • CDKN1A protein, human
  • Caspase Inhibitors
  • Cdkn1a protein, mouse
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins
  • Enzyme Inhibitors
  • Growth Inhibitors
  • Immunosuppressive Agents
  • Carbon Monoxide
  • JNK Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase Kinase 3
  • MAP Kinase Kinase Kinases
  • MAP3K3 protein, human
  • Map3k3 protein, mouse
  • MAP Kinase Kinase 4
  • Mitogen-Activated Protein Kinase Kinases
  • CASP8 protein, human
  • Casp8 protein, mouse
  • Caspase 8
  • Caspases
  • Guanylate Cyclase
  • Cyclic GMP